Human patient samples (both primary tumor and bone metastases), human prostate cancer cell lines and transgenic mouse models of prostate cancer have consistently demonstrated that AKT-mTOR signaling is increased in response to androgen/AR-directed blockade [11,13,24,291,292,293]. Here, MTOR is linked to prostate carcinoma.